Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothea Buck

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Expert Review of Neurotherapeutics|January 7, 2014
Biomarkers of treatment response in multiple sclerosisDorothea Buck, Bernhard Hemmer
Journal of Neurology|June 4, 2011
Treatment of multiple sclerosis: current concepts and future perspectivesDorothea Buck, Bernhard Hemmer
Annals of Neurology|February 5, 2013
Reply to Dr PandeyDorothea Buck, An Goris, Bernhard Hemmer
Neuropsychiatric Disease and Treatment|September 28, 2013
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaFlorian Castrop, Bernhard Haslinger, Bernhard Hemmer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 22, 2018
Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosisPatricia Lechner, Dorothea Buck, Lisa Sick, et al.
Journal of Neuroimmunology|March 19, 2010
The antibody response to oligodendrocyte specific protein in multiple sclerosisMuhammad Aslam, Sudhakar Reddy Kalluri, Sabine Cepok, et al.
Plos One|July 23, 2013
Fully Bayesian inference for structural MRI: application to segmentation and statistical analysis of T2-hypointensitiesPaul Schmidt, Volker J Schmid, Christian Gaser, et al.
Plos One|October 7, 2008
Effects of natalizumab treatment on Foxp3+ T regulatory cellsMax-Philipp Stenner, Anne Waschbisch, Dorothea Buck, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 13, 2015
Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelinationBenjamin Knier, Achim Berthele, Dorothea Buck, et al.
Journal of Autoimmunity|October 26, 2017
Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patientsSudhakar Reddy Kalluri, Verena Grummel, Zsuzsanna Hracsko, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Expert Review of Neurotherapeutics|January 7, 2014
Biomarkers of treatment response in multiple sclerosisDorothea Buck, Bernhard Hemmer
Journal of Neurology|June 4, 2011
Treatment of multiple sclerosis: current concepts and future perspectivesDorothea Buck, Bernhard Hemmer
Annals of Neurology|February 5, 2013
Reply to Dr PandeyDorothea Buck, An Goris, Bernhard Hemmer
Neuropsychiatric Disease and Treatment|September 28, 2013
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaFlorian Castrop, Bernhard Haslinger, Bernhard Hemmer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 22, 2018
Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosisPatricia Lechner, Dorothea Buck, Lisa Sick, et al.
Journal of Neuroimmunology|March 19, 2010
The antibody response to oligodendrocyte specific protein in multiple sclerosisMuhammad Aslam, Sudhakar Reddy Kalluri, Sabine Cepok, et al.
Plos One|July 23, 2013
Fully Bayesian inference for structural MRI: application to segmentation and statistical analysis of T2-hypointensitiesPaul Schmidt, Volker J Schmid, Christian Gaser, et al.
Plos One|October 7, 2008
Effects of natalizumab treatment on Foxp3+ T regulatory cellsMax-Philipp Stenner, Anne Waschbisch, Dorothea Buck, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 13, 2015
Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelinationBenjamin Knier, Achim Berthele, Dorothea Buck, et al.
Journal of Autoimmunity|October 26, 2017
Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patientsSudhakar Reddy Kalluri, Verena Grummel, Zsuzsanna Hracsko, et al.
Pageof 4